1. Home
  2. Products
  3. Customized ADCs
  4. PDGFRA
  5. Anti-PDGFR (Olaratumab)-MC-MMAF ADC

Anti-PDGFR (Olaratumab)-MC-MMAF ADC (CAT#: ADC-W-1708)

This ADC product is comprised of an anti-PDGFR monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • PDGFRA
  • Alternative Names
  • PDGFRA; platelet-derived growth factor receptor, alpha polypeptide; platelet-derived growth factor receptor alpha; CD140a; PDGFR2; PDGFR-alpha; PDGF-R-alpha; CD140a antigen; PDGFRA/BCR fusion; CD140 antigen-like family member A; platelet-derived growth factor receptor 2; alpha-type platelet-derived growth factor receptor; rearranged-in-hypereosinophilia-platelet derived growth factor receptor alpha fusion protein; CD140A; PDGFR-2; RHEPDGFRA; MGC74795;
  • Target Entrez Gene ID
  • 5156
  • Overview
  • This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.
  • Overview
  • Human Anti-PDGFRA IgG1-kappa antibody, Olaratumab
  • Generic name
  • Olaratumab
  • Host animal
  • Human
  • Name
  • MC (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-1708. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-1714 Anti-PDGFR (Tovetumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-1707 Anti-PDGFR (Olaratumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1706 Anti-PDGFR (Olaratumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-1709 Anti-PDGFR (Olaratumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-1717 Anti-PDGFR (Tovetumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
CAT# Product Name Linker Payload
ADC-W-2606 Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-322 Anti-CD19-Mc-MMAF ADC-1 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-515 Anti-EGFR-Mc-MMAF ADC-5 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-518 Anti-TM4SF1-Mc-LP2 ADC-2 Mc (maleimidocaproyl) LP2 (chemical name mc-3377)
CAT# Product Name Linker Payload
ADC-W-2567 Anti-MUC16 (Sofituzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2556 Anti-CD79B (Polatuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2600 Anti-GPNMB (Glembatumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2544 Anti-CD44 (Bivatuzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2591 Anti-EGFR (Cetuximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.